Nexalin Technology Stock Fundamentals
NXL Stock | USD 4.27 0.42 10.91% |
Nexalin Technology fundamentals help investors to digest information that contributes to Nexalin Technology's financial success or failures. It also enables traders to predict the movement of Nexalin Stock. The fundamental analysis module provides a way to measure Nexalin Technology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nexalin Technology stock.
At this time, Nexalin Technology's Interest Expense is quite stable compared to the past year. Selling And Marketing Expenses is expected to rise to about 2.1 M this year, although the value of Selling General Administrative will most likely fall to about 4 M. Nexalin | Select Account or Indicator |
Nexalin Technology Company Return On Equity Analysis
Nexalin Technology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nexalin Technology Return On Equity | -2.02 |
Most of Nexalin Technology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nexalin Technology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition |
Nexalin Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Nexalin Technology has a Return On Equity of -2.0223. This is 91.56% lower than that of the Health Care Equipment & Supplies sector and 76.84% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Nexalin Technology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nexalin Technology's current stock value. Our valuation model uses many indicators to compare Nexalin Technology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nexalin Technology competition to find correlations between indicators driving Nexalin Technology's intrinsic value. More Info.Nexalin Technology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Nexalin Technology's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Nexalin Technology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Nexalin Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nexalin Technology's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nexalin Technology could also be used in its relative valuation, which is a method of valuing Nexalin Technology by comparing valuation metrics of similar companies.Nexalin Technology is currently under evaluation in return on equity category among its peers.
Nexalin Technology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nexalin Technology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nexalin Technology's managers, analysts, and investors.Environmental | Governance | Social |
Nexalin Fundamentals
Return On Equity | -2.02 | ||||
Return On Asset | -1.19 | ||||
Operating Margin | (48.32) % | ||||
Current Valuation | 51.98 M | ||||
Shares Outstanding | 12.86 M | ||||
Shares Owned By Insiders | 23.29 % | ||||
Shares Owned By Institutions | 2.40 % | ||||
Number Of Shares Shorted | 622.63 K | ||||
Price To Book | 11.08 X | ||||
Price To Sales | 365.74 X | ||||
Revenue | 110.75 K | ||||
Gross Profit | 958.14 K | ||||
EBITDA | (5.69 M) | ||||
Net Income | (4.65 M) | ||||
Cash And Equivalents | 291.33 K | ||||
Cash Per Share | 0.06 X | ||||
Total Debt | 4.46 K | ||||
Current Ratio | 0.20 X | ||||
Book Value Per Share | 0.43 X | ||||
Cash Flow From Operations | (3.84 M) | ||||
Short Ratio | 0.56 X | ||||
Earnings Per Share | (0.65) X | ||||
Target Price | 3.0 | ||||
Beta | 3.57 | ||||
Market Capitalization | 54.92 M | ||||
Total Asset | 3.63 M | ||||
Retained Earnings | (77.04 M) | ||||
Working Capital | 3 M | ||||
Net Asset | 3.63 M |
About Nexalin Technology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nexalin Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nexalin Technology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nexalin Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for Next Year | ||
Current Deferred Revenue | 117 K | 104 K | |
Total Revenue | 110.7 K | 105.2 K | |
Cost Of Revenue | 25.7 K | 24.4 K | |
Stock Based Compensation To Revenue | 21.79 | 22.88 | |
Sales General And Administrative To Revenue | 52.20 | 54.81 | |
Research And Ddevelopement To Revenue | 17.35 | 18.22 | |
Capex To Revenue | 0.89 | 0.93 | |
Revenue Per Share | 0.02 | 0.01 | |
Ebit Per Revenue | (51.43) | (48.86) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Nexalin Technology Piotroski F Score and Nexalin Technology Altman Z Score analysis. For more information on how to buy Nexalin Stock please use our How to buy in Nexalin Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nexalin Technology. If investors know Nexalin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nexalin Technology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.02 | Quarterly Revenue Growth (0.24) | Return On Assets (1.19) | Return On Equity (2.02) |
The market value of Nexalin Technology is measured differently than its book value, which is the value of Nexalin that is recorded on the company's balance sheet. Investors also form their own opinion of Nexalin Technology's value that differs from its market value or its book value, called intrinsic value, which is Nexalin Technology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nexalin Technology's market value can be influenced by many factors that don't directly affect Nexalin Technology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nexalin Technology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nexalin Technology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nexalin Technology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.